Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
暂无分享,去创建一个
Karen A Gelmon | K. Gelmon | P. Ravdin | S. Chia | B. Norris | I. Olivotto | G. Davis | A. Coldman | C. Bajdik | Peter M Ravdin | Andrew J Coldman | Ivo A Olivotto | C. Speers | Chris D Bajdik | Caroline H Speers | Brian D Norris | Greg J Davis | Stephen K Chia
[1] R. Gelber,et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.
[2] P. Ravdin. A computer program to assist in making breast cancer adjuvant therapy decisions. , 1996, Seminars in oncology.
[3] R. Gelber,et al. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. , 2003, Breast.
[4] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[5] J. Vilcoq,et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. , 1989, International journal of radiation oncology, biology, physics.
[6] A. Lee,et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] V. Goel,et al. Compliance with practice guidelines for node-negative breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Weir,et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Mikael Lundin,et al. A web-based system for individualised survival estimation in breast cancer , 2003, BMJ : British Medical Journal.
[10] M. Levine,et al. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[11] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[12] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Lane,et al. Predicting recurrence in axillary-node negative breast cancer patients , 2004, Breast Cancer Research and Treatment.
[14] N. Weidner,et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Zedeler,et al. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. , 1995, European journal of cancer.
[16] P. Ravdin,et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Amiram Gafni,et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. , 2003, Journal of the National Cancer Institute.
[18] C. Loprinzi,et al. Understanding the utility of adjuvant systemic therapy for primary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Siminoff,et al. Doctor-patient communication about breast cancer adjuvant therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] I. Olivotto,et al. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. , 1997, British Journal of Cancer.